drugset
drugset / Trial / NCT02526017

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

NCT02526017 ↗

Phase 1 Completed 313 enrolled Five Prime Therapeutics, Inc. Bristol-Myers Squibb · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

Phase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.

Timeline

Start
2015-09-08
Primary completion
2019-11-18
Completion
2019-11-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabiralizumab Monoclonal antibody 1 mg/kg Intravenous
Subject Cabiralizumab Monoclonal antibody 2 mg/kg Intravenous
Subject Cabiralizumab Monoclonal antibody 4 mg/kg Intravenous
Subject Cabiralizumab Monoclonal antibody 6 mg/kg Intravenous
Subject Nivolumab Monoclonal antibody 3 mg/kg Intravenous

Indications

head and neck cancer malignant glioma malignant pancreatic neoplasm non-small cell lung carcinoma ovarian cancer renal cell carcinoma